Cargando…

Olaptesed pegol, an anti-CXCL12/SDF-1 Spiegelmer, alone and with bortezomib–dexamethasone in relapsed/refractory multiple myeloma: a Phase IIa Study

Detalles Bibliográficos
Autores principales:	Ludwig, H, Weisel, K, Petrucci, M T, Leleu, X, Cafro, A M, Garderet, L, Leitgeb, C, Foa, R, Greil, R, Yakoub-Agha, I, Zboralski, D, Vauléon, S, Dümmler, T, Beyer, D, Kruschinski, A, Riecke, K, Baumann, M, Engelhardt, M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2017
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5383929/ https://www.ncbi.nlm.nih.gov/pubmed/28074071 http://dx.doi.org/10.1038/leu.2017.5

Ejemplares similares

Safety, pharmacokinetics and pharmacodynamics of the anti‐hepcidin Spiegelmer lexaptepid pegol in healthy subjects
por: Boyce, M, et al.
Publicado: (2016)

Olaptesed pegol (NOX-A12) with bendamustine and rituximab: a phase IIa study in patients with relapsed/refractory chronic lymphocytic leukemia
por: Steurer, Michael, et al.
Publicado: (2019)

Inhibition of SDF-1-induced migration of oncogene-driven myeloid leukemia by the L-RNA aptamer (Spiegelmer), NOX-A12, and potentiation of tyrosine kinase inhibition
por: Weisberg, Ellen L., et al.
Publicado: (2017)

Randomized double-blind placebo-controlled PK/PD study on the effects of a single intravenous dose of the anti-hepcidin Spiegelmer NOX-H94 on serum iron during experimental human endotoxemia
por: Van Eijk, L, et al.
Publicado: (2013)

Spiegelmer-Based Sandwich Assay for Cardiac Troponin I Detection
por: Tolnai, Zoltán János, et al.
Publicado: (2020)

Nonbiodegradable Spiegelmer-Driven Colorimetric Biosensor for Bisphenol A Detection
por: Ren, Shuo, et al.
Publicado: (2022)

Blockade of SDF-1 after irradiation inhibits tumor recurrences of autochthonous brain tumors in rats
por: Liu, Shie-Chau, et al.
Publicado: (2014)

Crystal structure of a mirror-image L-RNA aptamer (Spiegelmer) in complex with the natural L-protein target CCL2
por: Oberthür, Dominik, et al.
Publicado: (2015)

5. Certolizumab Pegol for RA in pregnancy
por: Thorne, Iona, et al.
Publicado: (2017)

Indirect Treatment Comparison of Damoctocog Alfa Pegol versus Turoctocog Alfa Pegol as Prophylactic Treatment in Patients with Hemophilia A
por: Vashi, Parth, et al.
Publicado: (2021)

Patient Adherence and Efficacy of Certolizumab Pegol in the Management of Crohn’s Disease
por: Blonski, Wojciech, et al.
Publicado: (2012)

Renal sarcoidosis associated with certolizumab pegol treatment for psoriatic arthritis
por: Hum, Ryan M, et al.
Publicado: (2022)

Drug Induced Thrombotic Microangiopathy with Certolizumab Pegol
por: Baysal, Mehmet, et al.
Publicado: (2018)

P917: SELINEXOR, BORTEZOMIB, AND DEXAMETHASONE IN PATIENTS WITH PREVIOUSLY TREATED MULTIPLE MYELOMA: UPDATED RESULTS OF BOSTON TRIAL BY PRIOR THERAPIES
por: Mateos, Maria-Victoria, et al.
Publicado: (2023)

Mapping the certolizumab pegol epitope on TNF and comparison with infliximab, adalimumab and etanercept
por: Henry, Alistair I, et al.
Publicado: (2011)

Allogeneic Transplantation in Multiple Myeloma—Does It Still Have a Place?
por: Gahrton, Gösta, et al.
Publicado: (2020)

P901: POMALIDOMIDE, BORTEZOMIB, AND DEXAMETHASONE IN LENALIDOMIDE–PRETREATED MULTIPLE MYELOMA: A SUBANALYSIS OF OPTIMISMM BY FRAILTY
por: Oriol, A., et al.
Publicado: (2022)

Partial Response at Completion of Bortezomib-Thalidomide-Dexamethasone (VTd) Induction Regimen Upfront in Multiple Myeloma Does Not Preclude Response to VTd in Consolidation
por: Fouquet, Guillemette, et al.
Publicado: (2014)

Active axial spondyloarthritis: potential role of certolizumab pegol
por: Ranatunga, Sriya, et al.
Publicado: (2014)

Nonacog Beta Pegol: A Review in Haemophilia B
por: Syed, Yahiya Y.
Publicado: (2017)

Damoctocog Alfa Pegol: A Review in Haemophilia A
por: Paik, Julia, et al.
Publicado: (2019)

Two Dosing Regimens of Certolizumab Pegol in Patients With Active Rheumatoid Arthritis
por: Furst, D E, et al.
Publicado: (2015)

P886: EFFICACY, SURVIVAL AND SAFETY OF SELINEXOR, BORTEZOMIB AND DEXAMETHASONE (SVD) IN PATIENTS WITH LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA: SUBGROUP DATA FROM THE BOSTON TRIAL
por: Mateos, Maria-Victoria, et al.
Publicado: (2023)

Prefilled certolizumab pegol (Cimzia(®)) syringes for self-use in the treatment of rheumatoid arthritis
por: Rosa, J, et al.
Publicado: (2010)

Bortezomib
por: Rajappa, Senthil
Publicado: (2010)

SDF − a game changer?
por: Remtulla, A.
Publicado: (2020)

Progress on the Application of Bortezomib and Bortezomib-Based Nanoformulations
por: Liu, Jianhao, et al.
Publicado: (2021)

Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR
por: Spencer, Andrew, et al.
Publicado: (2018)

Synergistic Interaction of the Class IIa HDAC Inhibitor CHDI0039 with Bortezomib in Head and Neck Cancer Cells
por: Schrenk, Christian, et al.
Publicado: (2023)

P04: DARATUMUMAB PLUS BORTEZOMIB AND DEXAMETHASONE VERSUS BORTEZOMIB AND DEXAMETHASONE ALONE IN PATIENTS WITH PREVIOUSLY TREATED MULTIPLE MYELOMA: OVERALL SURVIVAL RESULTS FROM THE PHASE 3 CASTOR TRIAL
por: Sonneveld, P, et al.
Publicado: (2022)

Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk
por: Richard, Shambavi, et al.
Publicado: (2021)

Nelfinavir augments proteasome inhibition by bortezomib in myeloma cells and overcomes bortezomib and carfilzomib resistance
por: Kraus, M, et al.
Publicado: (2013)

Targeting nanomedicines in the treatment of rheumatoid arthritis: focus on certolizumab pegol
por: Barnes, Theresa, et al.
Publicado: (2007)

New biologics in the management of Crohn’s disease: focus on certolizumab pegol
por: Colombo, Elisabetta, et al.
Publicado: (2009)

Correction to: Nonacog Beta Pegol: A Review in Haemophilia B
por: Syed, Yahiya Y.
Publicado: (2018)

Population pharmacokinetic analysis of certolizumab pegol in patients with Crohn's disease
por: Wade, Janet R., et al.
Publicado: (2015)

Correction to: Damoctocog Alfa Pegol: A Review in Haemophilia A
por: Paik, Julia, et al.
Publicado: (2019)

Patient Satisfaction with CIMZIA(®) (Certolizumab Pegol) AutoClicks(®) in the UK
por: Bailey, Kathryn, et al.
Publicado: (2020)

Certolizumab pegol – Tumor necrosis factor inhibitor for refractory uveitis
por: Sharon, Yael, et al.
Publicado: (2020)

Certolizumab pegol treatment for leg ulcers due to rheumatoid vasculitis
por: Meling, Maureen Tania, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_nu6ogebsglf38m0a6jbtsep930